This site is intended only for healthcare professionals resident in Thailand

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Supporting ResourcesEventsMaterialsVideosAboutAboutCOVID-19 overviewLong COVIDMechanism of diseaseTransmissionVariantsPreparePrepareVaccination overviewVaccination typesWaning & boostingGuidelines for managing COVID-19DiagnoseDiagnoseSigns & symptomsHigh risk patientsTestingTreatTreatTreatment guidelinesTreatment optionsSupporting ResourcesSupporting ResourcesEventsMaterialsVideos
The possible consequences of SARS-CoV-2 infection 

Long COVID has similarities to other post-viral syndromes, but there is still limited understanding about the nuances of this disease. In this bite-sized 15-minute podcast two experts discuss:

  • What is long COVID?
  • Patient sub-group susceptibility to long COVID
  • Treatment for long-term impairments from COVID-19 
  • Long COVID impacts and how to support different patient groups 
 Listen to the full discussion between Professor David Weber and Dr Danilo Buonsenso Explore morePrepare

Find out more about different vaccine types, waning immunity, and boosting by clicking on the buttons below.

 Vaccine types Loading
Waning & boosting
Loading
Guidelines for
managing COVID-19
LoadingReferences:NICE, RCGP, and SIGN. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available at https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 (accessed January 2023).World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (accessed January 2023).Davis HE, et al. EClinicalMedicine 2021;38:101019.Whitaker M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2021.06.28.21259452v1 (accessed January 2023).Xie Y, et al. Nat Commun. 2021;12(1):6571.Staffolani S, et al. Infez Med 2022;30(1):22–29.Lopez-Leon S, et al. Sci Rep 2021;11(1):16144.ONS. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. 2021. Available at https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021/pdf (accessed January 2023).KCE report 344Cs. Long COVID: pathophysiology – epidemiology and patient needs. 2021. Available at https://www.kce.fgov.be/sites/default/files/atoms/files/KCE_344C_Long_Covid_Short_report.pdf (accessed January 2023).Behnood SA, et al. J Infect 2022;84(2):158–170.Staffolani S, et al. Infez Med 2022;30(1):22–29.Trisha Greenhalgh T, et al. BMJ 2020;370:m3026.https://www.yalemedicine.org/conditions/long-covid-postacute-sequelae-of-sars-cov-2-infection-pasc (accessed January 2023)Coughlin SS. Public Health Rev. 2012;34(2).Oliver BG, et al. Eur Respir J. 2014;44(6):1666-81.Thompson EJ, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2021.06.24.21259277v1.full (accessed January 2023).Whitaker M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2021.06.28.21259452v1 (accessed January 2023).Osmanov IM, et al. Eur Respir J 2022;59(2):2101341.Ortona E, et al. Cell Death Discov 2021;7(1):77.NICE, RCGP, and SIGN. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available at https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 (accessed January 2023).Nature News. Can drugs reduce the risk of long COVID? What scientists know so far. 25 March 2022. Available at https://www.nature.com/articles/d41586-022-00823-y (accessed January 2023).Greenhalgh T, et al. Am Fam Physician 2020;102(12):716–717.NICE, RCGP, and SIGN. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available at https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 (accessed January 2023).Buonsenso D, et al. J Paediatr Child Health 2022;58:201–202.Mayo Clinic. COVID-19 (coronavirus): Long-term effects. Available at https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351 (accessed January 2023).Xie Y, et al. Nature Med 2022;28:583–590.Cedars Sinai. Three big questions about long COVID. Available at https://www.cedars-sinai.org/discoveries/three-big-questions-about-long-covid.html (accessed January 2023).Ward H, et al. Lancet 2021;398(10316):2057–2059.Briggs A, et al. Nature 2021;593:502–505.Walker AJ, et al. Br J Gen Pract 2021;71:e806–814.About Help restore protection with bivalent boosters

Find out more about how adaptive vaccines may help to combat recent variants

 Learn more Loading
PP-CVV-THA-0393

Adverse events should be reported. Reporting forms and information can be found at https://www.pfizersafetyreporting.com/#/en

 

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This website is intended only for healthcare professionals registered in Thailand. If you are a non-registered healthcare professional in Thailand wishing to access general health and medical information, please visit [www.pfizer.co.th].

This website is brought to you by Pfizer (Thailand) Limited. 
 
You are now leaving the PfizerPro Thailand website
 ​
You are being directed to a third-party website. Please note that this third-party website is not controlled by PfizerPro Thailand or subject to our privacy policy. Thank you for visiting our site. We hope your visit was informative and enjoyable.
PP-UNP-THA-0485​
You are now leaving the PfizerPro Thailand website You are being directed to a third-party website. Please note that this third-party website is not controlled by PfizerPro Thailand or subject to our privacy policy. Thank you for visiting our site. We hope your visit was informative and enjoyable.